title: [Roles of hyperphosphatemia in vascular calcification].
abstract: Derangemenst of mineral metabolism including hyperphosphatemia occur along with progression of chronic kidney disease (CKD) . Recent clinical studies suggest that hyperphosphatemia is a major risk factor for vascular calcification and cardiovascular mortality in dialysis patients. Two pathophysiological processes are involved in the development of vascular calcification : apoptosis and phenotypic transition to chondrocytes or osteoblasts (chondro-/osteogenic differentiation) . Inorganic phosphate has been demonstrated to induce apoptosis and calcification of vascular smooth muscle cells through inhibiting gas6/Axl/PI3K/Akt pathway (cell survival pathway) . Moreover, inorganic phosphate has been shown to promote in vitro calcification of vascular wall cells by stimulating osteoblastic differentiation through a type III sodium-dependent phosphate co-transporter (PiT-1) . These molecular mechanisms suggest that hyperphosphatemia may play a pivotal role in progression of vascular calcification in CKD.
authors.affiliation: Osaka City University Graduate School of Medicine, Department of Cardiovascular Medicine.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Shioi
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Nishizawa
mesh_terms: D017209:Apoptosis; D002114:Calcinosis; D002454:Cell Differentiation; D002908:Chronic Disease; D006801:Humans; D054559:Hyperphosphatemia / Q000209:etiology*; D007674:Kidney Diseases / Q000150:complications*; D010006:Osteoblasts / Q000166:cytology; D012307:Risk Factors; D050611:Sodium-Phosphate Cotransporter Proteins, Type III / Q000502:physiology; D014652:Vascular Diseases / Q000209:etiology*
chemical_list: D050611:Sodium-Phosphate Cotransporter Proteins, Type III